Long Noncoding RNAs in the Heart

Rayner, Katey J.

doi:10.1161/circgenetics.116.001413

Cited by 11 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, with the emergence of sequencing techniques, the widespread existence of lncRNAs in cardiovascular development and diseases has been confirmed, and their action mechanisms and important biological functions have gradually been elucidated [ 10 , 11 ]. In fact, lncRNAs play crucial roles in regulating cell transformation and organogenesis, as well as in mammalian heart development and cellular lineage [ 12 – 14 ]. In a study conducted in mice, Braveheart ( Bvht ), known as a novel long noncoding RNA, was identified as a critical regulator of cardiovascular-associated cell differentiation and revealed to be required for the development of nascent mesoderm [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Plasma Long Noncoding RNA ANRIL for In-Stent Restenosis

Wang

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundIn-stent restenosis (ISR) remains a major cause of failure of contemporary percutaneous revascularization therapies. Invasive biomarkers to improve the prognosis of ISR should be considered. This study aimed to investigate the association between plasma ANRIL expression and ISR.Material/MethodsA total of 444 patients were included in this research. Serial coronary angiography was performed at baseline (before and after intervention) and within 36 months’ follow-up. ISR was defined as >50% diameter stenosis at follow-up. ANRIL expression was quantified using reverse transcription-PCR. An area under the ROC curve (auROC) was generated to assess the diagnostic values of ANRIL. Logistic regression models were used to assess the independent risk factors for ISR.ResultsPlasma ANRIL expression was significantly increased in patients with ISR, as compared with that in patients without ISR (1.6 [1.1–2.5] vs. 0.9 [0.6–1.3], P<0.001). The auROC (95% confidence interval [CI]) of plasma ANRIL in diagnosing ISR was 0.745 (0.687–0.811). Multiple logistic regression models indicated that drinking (odds ratio [OR]=2.09, 95% CI: 1.08–4.04, P=0.028), hypertension (OR=2.01, 95% CI: 1.14–3.57, P=0.017), diabetes (OR=3.15, 95% CI: 1.63–3.57, P<0.001), low-density lipoprotein (OR=3.14, 95% CI: 1.57–6.31, P=0.001), and ANRIL (OR=2.21, 95% CI: 1.68–2.92, P<0.001) were the independent risk factors for ISR.ConclusionsWe found that higher ANRIL expression is associated with ISR, indicating that ANRIL may be an optimal prognostic factor for ISR.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Plasma Long Noncoding RNA ANRIL for In-Stent Restenosis

Wang

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Several consortium projects, such as the Encyclopedia of DNA Elements (ENCODE) 12 and Functional Annotation of the Mammalian Genome (FANTOM) 13 have reported that ncRNAs substantially outnumber protein-coding genes and perform various specific roles in controlling gene expression and function 14 . Thus, these ncRNAs have emerged as new key players in the cardiovascular regulatory network 15 . Based on the size of their mature transcripts, ncRNAs can be broadly classified as small (<200 nucleotide [nt]) RNAs, large (>200 nt) ncRNAs (lncRNAs), and regulatory RNAs (e.g., rRNA and tRNA).…”

Section: Introductionmentioning

confidence: 99%

Systematic identification and characterization of cardiac long intergenic noncoding RNAs in zebrafish

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Long intergenic noncoding RNAs (lincRNAs) are increasingly recognized as potential key regulators of heart development and related diseases, but their identities and functions remain elusive. In this study, we sought to identify and characterize the cardiac lincRNA transcriptome in the experimentally accessible zebrafish model by integrating bioinformatics analysis with experimental validation. By conducting genome-wide RNA sequencing profiling of zebrafish embryonic hearts, adult hearts, and adult muscle, we generated a high-confidence set of 813 cardiac lincRNA transcripts, 423 of which are novel. Among these lincRNAs, 564 are expressed in the embryonic heart, and 730 are expressed in the adult heart, including 2 novel lincRNAs, TCONS_00000891 and TCONS_00028686, which exhibit cardiac-enriched expression patterns in adult heart. Using a method similar to a fetal gene program, we identified 51 lincRNAs with differential expression patterns between embryonic and adult hearts, among which TCONS_00009015 responded to doxorubicin-induced cardiac stress. In summary, our genome-wide systematic identification and characterization of cardiac lincRNAs lays the foundation for future studies in this vertebrate model to elucidate crucial roles for cardiac lincRNAs during heart development and cardiac diseases.

show abstract

“…It is also attractive to consider that recapitulation of developmental gene expression programmes may be central to susceptibility to development of SSc since it can be envisaged as a disease of perturbed connective tissue repair. There is a strong precedent for the same genetic pathways and programmes that are used in embryonic and post-natal growth and development to be recapitulated in acquired disease [26]. This may also fit with the model of SSc being a susceptibility genotype that we have recently postulated for the key complication of pulmonary arterial hypertension [27].…”

Section: Discussionmentioning

confidence: 68%

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature

et al. 2017

View full text Add to dashboard Cite

BackgroundSystemic sclerosis (SSc; scleroderma) is an uncommon autoimmune rheumatic disease characterised by autoimmunity, vasculopathy and fibrosis. Gene expression profiling distinguishes scleroderma from normal skin, and can detect different subsets of disease, with potential to identify prognostic biomarkers of organ involvement or response to therapy. We have performed gene expression profiling in skin samples from patients with limited cutaneous SSc (lcSSc).MethodsTotal RNA was extracted from clinically uninvolved skin biopsies of 15 patients with lcSSc and 8 healthy controls (HC). Gene expression profiling was performed on a DNA oligonucleotide microarray chip. Differentially expressed genes (DEG) were identified using significance analysis of microarrays (SAM). Functional enrichment analysis of gene signatures was done via g:Profiler.ResultsThere were 218 DEG between lcSSc and HC samples (false discovery rate <10%): 181/218 DEG were upregulated in lcSSc samples. Hierarchical clustering of DEG suggested the presence of two separate groups of lcSSc samples: “limited 1” and “limited 2”. The limited-1 group (13 samples, 10 unique patients) showed upregulation of genes involved in cell adhesion, cardiovascular system (CVS) development, extracellular matrix and immune and inflammatory response. The CVS development signature was of particular interest as its genes showed very strong enrichment in response to wounding, response to transforming growth factor (TGF)-β and kinase cascade. Neither limited-2 samples (six samples, five unique patients) nor HC samples showed functional enrichment. There were no significant differences in demographic or clinical parameters between these two groups. These results were confirmed using a second independent cohort.ConclusionsOur study suggests the presence of molecular subsets in lcSSc based on gene expression profiling of biopsies from uninvolved skin. This may reflect important differences in pathogenesis within these patient groups. We identify differential expression of a subset of genes that relate to CVS and are enriched in fibrotic signalling. This may shed light on mechanisms of vascular disease in SSc. The enrichment in profibrotic profile suggests that dysregulated gene expression may contribute to vasculopathy and fibrosis in different disease subsets.Electronic supplementary materialThe online version of this article (doi:10.1186/s13075-017-1360-7) contains supplementary material, which is available to authorized users.

show abstract

Long Noncoding RNAs in the Heart

Cited by 11 publications

References 9 publications

Prognostic Value of Plasma Long Noncoding RNA ANRIL for In-Stent Restenosis

Prognostic Value of Plasma Long Noncoding RNA ANRIL for In-Stent Restenosis

Systematic identification and characterization of cardiac long intergenic noncoding RNAs in zebrafish

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature

Contact Info

Product

Resources

About